Gout presents a classic conundrum: Despite the fact that effective treatments are available, the management of the disease is widely recognized as suboptimal; only a minority of patients who are candidates for urate-lowering therapy actually receive it. Patient adherence to therapy is low and tails off even during the first year of treatment, due in part to a lack of knowledge about the disease and the long-term damage it can cause.
In this activity, Dr. Paul Doghramji talks with Nick, a 65-year-old patient with gout. Together, they review the patient’s medical history, and discuss the advice and treatment he received about his gout over the past 2 decades. The need to address underlying hyperuricemia in patients with gout is explored, as are identifying and addressing barriers to therapeutic adherence.